497 related articles for article (PubMed ID: 19500981)
1. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.
Ryckmans T; Edwards MP; Horne VA; Correia AM; Owen DR; Thompson LR; Tran I; Tutt MF; Young T
Bioorg Med Chem Lett; 2009 Aug; 19(15):4406-9. PubMed ID: 19500981
[TBL] [Abstract][Full Text] [Related]
2. Optimization of triaryl bis-sulfones as cannabinoid-2 receptor ligands.
Lavey BJ; Kozlowski JA; Shankar BB; Spitler JM; Zhou G; Yang DY; Shu Y; Wong MK; Wong SC; Shih NY; Wu J; McCombie SW; Rizvi R; Wolin RL; Lunn CA
Bioorg Med Chem Lett; 2007 Jul; 17(13):3760-4. PubMed ID: 17466519
[TBL] [Abstract][Full Text] [Related]
3. Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.
Worm K; Zhou QJ; Saeui CT; Green RC; Cassel JA; Stabley GJ; DeHaven RN; Conway-James N; LaBuda CJ; Koblish M; Little PJ; Dolle RE
Bioorg Med Chem Lett; 2008 May; 18(9):2830-5. PubMed ID: 18430570
[TBL] [Abstract][Full Text] [Related]
4. Novel benzimidazole derivatives as selective CB2 agonists.
Pagé D; Balaux E; Boisvert L; Liu Z; Milburn C; Tremblay M; Wei Z; Woo S; Luo X; Cheng YX; Yang H; Srivastava S; Zhou F; Brown W; Tomaszewski M; Walpole C; Hodzic L; St-Onge S; Godbout C; Salois D; Payza K
Bioorg Med Chem Lett; 2008 Jul; 18(13):3695-700. PubMed ID: 18522867
[TBL] [Abstract][Full Text] [Related]
5. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
6. Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.
Ohta H; Ishizaka T; Yoshinaga M; Morita A; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Sep; 17(18):5133-5. PubMed ID: 17643986
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
8. 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors.
Liddle J; Bamborough P; Barker MD; Campos S; Cousins RP; Cutler GJ; Hobbs H; Holmes DS; Ioannou C; Mellor GW; Morse MA; Payne JJ; Pritchard JM; Smith KJ; Tape DT; Whitworth C; Williamson RA
Bioorg Med Chem Lett; 2009 May; 19(9):2504-8. PubMed ID: 19349179
[TBL] [Abstract][Full Text] [Related]
9. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K
Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813
[TBL] [Abstract][Full Text] [Related]
10. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT
Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038
[TBL] [Abstract][Full Text] [Related]
11. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
12. Identification of small molecule agonists of the motilin receptor.
Heightman TD; Conway E; Corbett DF; Macdonald GJ; Stemp G; Westaway SM; Celestini P; Gagliardi S; Riccaboni M; Ronzoni S; Vaidya K; Butler S; McKay F; Muir A; Powney B; Winborn K; Wise A; Jarvie EM; Sanger GJ
Bioorg Med Chem Lett; 2008 Dec; 18(24):6423-8. PubMed ID: 18980843
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands.
Woods CR; Hack MD; Allison BD; Phuong VK; Rosen MD; Morton MF; Prendergast CE; Barrett TD; Shankley NP; Rabinowitz MH
Bioorg Med Chem Lett; 2007 Dec; 17(24):6905-9. PubMed ID: 18029172
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
[TBL] [Abstract][Full Text] [Related]
15. Replacing alkyl sulfonamide with aromatic sulfonamide in sulfonamide-type RXR agonists favors switch towards antagonist activity.
Morishita K; Yakushiji N; Ohsawa F; Takamatsu K; Matsuura N; Makishima M; Kawahata M; Yamaguchi K; Tai A; Sasaki K; Kakuta H
Bioorg Med Chem Lett; 2009 Feb; 19(3):1001-3. PubMed ID: 19095448
[TBL] [Abstract][Full Text] [Related]
16. Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Sellitto I; Le Bourdonnec B; Worm K; Goodman A; Savolainen MA; Chu GH; Ajello CW; Saeui CT; Leister LK; Cassel JA; Dehaven RN; Labuda CJ; Koblish M; Little PJ; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2010 Jan; 20(1):387-91. PubMed ID: 19919895
[TBL] [Abstract][Full Text] [Related]
17. Morpholine containing CB2 selective agonists.
Zindell R; Riether D; Bosanac T; Berry A; Gemkow MJ; Ebneth A; Löbbe S; Raymond EL; Thome D; Shih DT; Thomson D
Bioorg Med Chem Lett; 2009 Mar; 19(6):1604-9. PubMed ID: 19243942
[TBL] [Abstract][Full Text] [Related]
18. Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Yamaguchi T; Tomishima Y; Futaki N; Toda Y; Saito S
Bioorg Med Chem; 2008 Feb; 16(3):1111-24. PubMed ID: 18006322
[TBL] [Abstract][Full Text] [Related]
19. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands.
Bhattacharjee H; Gurley SN; Moore BM
Bioorg Med Chem Lett; 2009 Mar; 19(6):1691-3. PubMed ID: 19230659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
